{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:21:33Z","timestamp":1786735293168,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejso.2025.111161","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:12:59Z","timestamp":1762215179000},"page":"111161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Exploring PIPAC for managing platinum resistant and refractory ovarian cancer with peritoneal spread: A collaborative multi-institutional study"],"prefix":"10.1016","volume":"52","author":[{"given":"Marco","family":"Tesei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7236-8028","authenticated-orcid":false,"given":"Elisa","family":"Scarpelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1414-0106","authenticated-orcid":false,"given":"Barbara","family":"Costantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7437-6866","authenticated-orcid":false,"given":"Enrico","family":"Fiuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camelia Alexandra","family":"Coada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9653-6692","authenticated-orcid":false,"given":"Francesco","family":"Mezzapesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-335X","authenticated-orcid":false,"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8841-6531","authenticated-orcid":false,"given":"Pierandrea","family":"De Iaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2424-2691","authenticated-orcid":false,"given":"Giuseppe","family":"Vizzielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Myriam","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejso.2025.111161_bib1","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/cancers15020407","article-title":"Diagnostic and therapeutic pathway of advanced ovarian cancer with peritoneal metastases","volume":"15","author":"Ghirardi","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ejso.2025.111161_bib2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2025.111161_bib3","article-title":"Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer","volume":"3","author":"van de Vrie","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ejso.2025.111161_bib4","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"\"Platinum resistant\" ovarian cancer: what is it, who to treat and how to measure benefit?","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"23","key":"10.1016\/j.ejso.2025.111161_bib5","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejso.2025.111161_bib6","doi-asserted-by":"crossref","first-page":"947","DOI":"10.21873\/anticanres.15554","article-title":"Computed tomography-assessed skeletal muscle index and skeletal muscle radiation attenuation in patients with ovarian cancer treated with primary surgery followed by platinum-based chemotherapy: a single-center Italian study","volume":"42","author":"Gadducci","year":"2022","journal-title":"Anticancer Res"},{"issue":"8","key":"10.1016\/j.ejso.2025.111161_bib7","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1093\/annonc\/mdx229","article-title":"Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy","volume":"28","author":"Roncolato","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2025.111161_bib8","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","article-title":"Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review","volume":"9","author":"Richardson","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejso.2025.111161_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ygyno.2024.12.011","article-title":"Incorporating immune checkpoint inhibitors in epithelial ovarian cancer","volume":"193","author":"Bogani","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.111161_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/cancers12010034","article-title":"Overcoming drug resistance by taking advantage of physical principles: pressurized intraperitoneal aerosol chemotherapy (PIPAC)","volume":"12","author":"Nadiradze","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.ejso.2025.111161_bib11","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3390\/cancers16081559","article-title":"Pressurised intraperitoneal aerosolised chemotherapy: results from the first hundred consecutive procedures","volume":"16","author":"Hoskovec","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ejso.2025.111161_bib12","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1245\/s10434-023-14648-0","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) applied to platinum-resistant recurrence of ovarian tumor: a single-institution experience (PARROT trial)","volume":"31","author":"Vizzielli","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2025.111161_bib13","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00404-024-07586-z","article-title":"Efficacy and safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in ovarian cancer: a systematic review of current evidence","volume":"310","author":"Pavone","year":"2024","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"10.1016\/j.ejso.2025.111161_bib14","doi-asserted-by":"crossref","DOI":"10.1515\/pp-2018-0111","article-title":"Pressurized intraperitoneal aerosol chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum-resistant ovarian cancer: study protocol for a randomized controlled trial","volume":"4","author":"Somashekhar","year":"2019","journal-title":"Pleura Peritoneum"},{"key":"10.1016\/j.ejso.2025.111161_bib15","series-title":"Linee guida tumori peritoneali primitivi e secondari [Internet]. Edizione 2024; aggiornamento 18 dicembre 2024","year":"2024"},{"issue":"10","key":"10.1016\/j.ejso.2025.111161_bib16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2025.111161_bib17","doi-asserted-by":"crossref","first-page":"642.e1","DOI":"10.1016\/j.ajog.2008.06.052","article-title":"Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma","volume":"199","author":"Fagotti","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.ejso.2025.111161_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2018.05.001","article-title":"A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis","volume":"150","author":"Tempfer","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2025.111161_bib19","doi-asserted-by":"crossref","DOI":"10.1515\/pp-2018-0108","article-title":"Treatment of peritoneal carcinomatosis with pressurized intraperitoneal aerosol chemotherapy (PIPAC-OPC2)","volume":"3","author":"Graversen","year":"2018","journal-title":"Pleura Peritoneum"},{"issue":"6","key":"10.1016\/j.ejso.2025.111161_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2023.101014","article-title":"Prognostic role of the peritoneal cancer index in ovarian cancer patients who undergo cytoreductive surgery: a meta-analysis","volume":"47","author":"Yang","year":"2023","journal-title":"Curr Probl Cancer"},{"issue":"4","key":"10.1016\/j.ejso.2025.111161_bib21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ejso.2021.10.028","article-title":"Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: technical aspects and treatment protocols","volume":"48","author":"H\u00fcbner","year":"2022","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2025.111161_bib22","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.ejso.2019.05.007","article-title":"Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: a multicenter study","volume":"45","author":"Sgarbura","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2025.111161_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The clavien-dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.ejso.2025.111161_bib25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejso.2025.111161_bib26","series-title":"R: a language and environment for statistical computing","year":"2021"},{"issue":"2","key":"10.1016\/j.ejso.2025.111161_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1515\/pp-2023-0004","article-title":"Pressurized intraperitoneal aerosol chemotherapy, reasons for interrupting treatment: a systematic review of the literature","volume":"8","author":"Ezanno","year":"2023","journal-title":"Pleura Peritoneum"},{"issue":"3","key":"10.1016\/j.ejso.2025.111161_bib28","first-page":"231","article-title":"The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer","volume":"1","author":"Meyer","year":"2016","journal-title":"Expert Rev Qual Life Cancer Care"},{"issue":"9","key":"10.1016\/j.ejso.2025.111161_bib29","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/ijgc-2021-002951","article-title":"European society of gynaecological oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery","volume":"31","author":"Fotopoulou","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"13","key":"10.1016\/j.ejso.2025.111161_bib30","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.111161_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ygyno.2024.01.027","article-title":"Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer","volume":"184","author":"Moffat","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"24","key":"10.1016\/j.ejso.2025.111161_bib32","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.3390\/cancers16244229","article-title":"Efficacy and insights from an extensive series of cytoreductive surgery for peritoneal neoplasms: a high-volume single-center experience","volume":"16","author":"Aulicino","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ejso.2025.111161_bib33","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/cancers15041125","article-title":"Ten years of pressurized intraperitoneal aerosol chemotherapy (PIPAC): a systematic review and meta-analysis","volume":"15","author":"Di Giorgio","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.ejso.2025.111161_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2023.107250","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in patients with ovarian cancer: a systematic review","volume":"49","author":"Taliento","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2025.111161_bib35","doi-asserted-by":"crossref","unstructured":"Orgad R, Bakrin N, Bonnefoy I, et al. Number of pressurized intraperitoneal aerosol chemotherapy (PIPAC) treatments is associated with longer survival: analysis of a large prospective cohort of patients with unresectable peritoneal surface malignancies. Ann Surg. Published online July 23, 2024. doi:10.1097\/SLA.0000000000006447.","DOI":"10.1097\/SLA.0000000000006447"},{"issue":"1","key":"10.1016\/j.ejso.2025.111161_bib36","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12957-016-1008-0","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"14","author":"Girshally","year":"2016","journal-title":"World J Surg Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.ejso.2025.111161_bib37","article-title":"CRS-HIPEC following neoadjuvant bidirectional pressurized intraperitoneal aerosol chemotherapy (PIPAC) with systemic chemotherapy in primarily advanced inoperable epithelial ovarian cancer","volume":"34","author":"Kumar","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2025.111161_bib38","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1186\/s12885-021-07955-w","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC): increased intraperitoneal pressure does not affect distribution patterns but leads to deeper penetration depth of doxorubicin in a sheep model","volume":"21","author":"Mimouni","year":"2021","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.ejso.2025.111161_bib39","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.3390\/jcm13113320","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of gastric cancer: feasibility, efficacy and safety\u2014a systematic review and meta-analysis","volume":"13","author":"Ramalho-Vasconcelos","year":"2024","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.ejso.2025.111161_bib40","first-page":"159","article-title":"Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal regression grading score (PRGS)","volume":"1","author":"Solass","year":"2016","journal-title":"Pleura Peritoneum"},{"issue":"4","key":"10.1016\/j.ejso.2025.111161_bib41","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1515\/pp-2024-0008","article-title":"Pressurized intrathoracic aerosol chemotherapy (PITAC) directed therapy of patients with malignant pleural effusion and pleural metastasis","volume":"9","author":"Hansen","year":"2024","journal-title":"Pleura Peritoneum"},{"issue":"1","key":"10.1016\/j.ejso.2025.111161_bib42","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/cancers11010078","article-title":"Variation in clinical application of hyperthermic intraperitoneal chemotherapy: a review","volume":"11","author":"Rfcpa","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ejso.2025.111161_bib43","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2174\/1871520615666160504095433","article-title":"New poly(3-hydroxybutyrate) microparticles with paclitaxel sustained release for intraperitoneal administration","volume":"17","author":"Bonartsev","year":"2017","journal-title":"Anti Cancer Agents Med Chem"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325015896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325015896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T07:58:52Z","timestamp":1767945532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798325015896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0748798325015896"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111161","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring PIPAC for managing platinum resistant and refractory ovarian cancer with peritoneal spread: A collaborative multi-institutional study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.111161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111161"}}